W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza III
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Miasta: Katowice, Opole, Przemyśl, ŁódźWiek: od 18 latSponsor: Bristol-Myers Squibb Services Unlimited Company
W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza III
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)…
Miasta: Katowice, Lublin, Opole, PrzemyślWiek: od 18 latSponsor: Bristol-Myers Squibb Services Unlimited Company
W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza I/II
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular…
Miasta: Gdańsk, Warszawa, WrocławWiek: od 18 latSponsor: Bristol-Myers Squibb Services Unlimited Company
RekrutujeFaza II/III
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously…
Miasta: Brzozów, Gdańsk, Gliwice, Jelenia Góra i 5 innych miastWiek: od 18 latSponsor: Bristol-Myers Squibb Services Unlimited Company
W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza II/III
ROSETTA Gastric-204: A Blinded, Randomized, Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy in Participants with…
Miasta: Gliwice, Jelenia Góra, Opole, Warszawa i 1 inne miastoWiek: od 18 latSponsor: Bristol-Myers Squibb Services Unlimited Company
Rekrutacja wkrótceFaza II
A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)
Miasta: Bydgoszcz, GdańskWiek: od 18 latSponsor: Bristol-Myers Squibb